These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35158284)

  • 1. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity.
    Zhao H; Li L; Liu J; Mai R; Chen J; Chen J
    Bioorg Chem; 2022 Apr; 121():105652. PubMed ID: 35158284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel Quinazoline-based KRAS G12C inhibitors as potential anticancer agents.
    Li L; Zhao H; Peng X; Liu J; Mai R; Chen J; Lin L; Chen T; Yan J; Shi J; Chen J
    Bioorg Med Chem; 2022 Oct; 71():116962. PubMed ID: 35987104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
    Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
    Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of 4(1H)-quinolinone and urea derivatives as KRAS
    Cheng R; Lv X; Bu H; Xu Q; Wu J; Xie K; Tang J; Wang L; Zhuang J; Zhang Y; Zhang Y; Yan C; Lai Y
    Eur J Med Chem; 2022 Dec; 244():114808. PubMed ID: 36228411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel coumarin-based KRAS-G12C inhibitors from virtual screening and Rational structural optimization.
    Shi JT; Hou SJ; Cheng L; Zhang HJ; Mu HX; Wang QS; Wang ZY; Chen SW
    Bioorg Chem; 2024 Jul; 148():107467. PubMed ID: 38772290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity.
    Li L; Wu Y; Yang Z; Xu C; Zhao H; Liu J; Chen J; Chen J
    Bioorg Chem; 2021 Dec; 117():105447. PubMed ID: 34715575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
    Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
    Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-1553: A novel KRAS
    Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
    Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ganoderma microsporum immunomodulatory protein combined with KRAS
    Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
    Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Preclinical Evaluation of Radiolabeled Covalent G12C-Specific Inhibitors for Direct Imaging of the Oncogenic KRAS Mutant.
    Zhang Z; Wang X; Ye J; Liu H; Fang J; Zhang M; Li Y; Huang J; Zhang D; Wang J; Zhang X
    Mol Pharm; 2021 Sep; 18(9):3509-3518. PubMed ID: 34410132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design, synthesis and pharmacological evaluation of bicyclic and tetracyclic pyridopyrimidinone analogues as new KRAS
    Xiao X; Lai M; Song Z; Geng M; Ding J; Xie H; Zhang A
    Eur J Med Chem; 2021 Mar; 213():113082. PubMed ID: 33309163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening.
    Li L; Liu J; Yang Z; Zhao H; Deng B; Ren Y; Mai R; Huang J; Chen J
    Eur J Med Chem; 2022 Apr; 233():114243. PubMed ID: 35276423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of a novel KRAS G12C inhibitor ASP2453 that shows potent anti-tumour activity in KRAS G12C-mutated preclinical models.
    Nakayama A; Nagashima T; Nishizono Y; Kuramoto K; Mori K; Homboh K; Yuri M; Shimazaki M
    Br J Cancer; 2022 Mar; 126(5):744-753. PubMed ID: 34795410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Landscape of
    Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
    JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
    Holderfield M; Lee BJ; Jiang J; Tomlinson A; Seamon KJ; Mira A; Patrucco E; Goodhart G; Dilly J; Gindin Y; Dinglasan N; Wang Y; Lai LP; Cai S; Jiang L; Nasholm N; Shifrin N; Blaj C; Shah H; Evans JW; Montazer N; Lai O; Shi J; Ahler E; Quintana E; Chang S; Salvador A; Marquez A; Cregg J; Liu Y; Milin A; Chen A; Ziv TB; Parsons D; Knox JE; Klomp JE; Roth J; Rees M; Ronan M; Cuevas-Navarro A; Hu F; Lito P; Santamaria D; Aguirre AJ; Waters AM; Der CJ; Ambrogio C; Wang Z; Gill AL; Koltun ES; Smith JAM; Wildes D; Singh M
    Nature; 2024 May; 629(8013):919-926. PubMed ID: 38589574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HER2 mediates clinical resistance to the KRAS
    Ho CSL; Tüns AI; Schildhaus HU; Wiesweg M; Grüner BM; Hegedus B; Schuler M; Schramm A; Oeck S
    Eur J Cancer; 2021 Dec; 159():16-23. PubMed ID: 34715459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient targeted oncogenic KRAS
    Yang F; Wen Y; Wang C; Zhou Y; Zhou Y; Zhang ZM; Liu T; Lu X
    Eur J Med Chem; 2022 Feb; 230():114088. PubMed ID: 35007863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of ASP6918, a KRAS G12C inhibitor: Synthesis and structure-activity relationships of 1-{2,7-diazaspiro[3.5]non-2-yl}prop-2-en-1-one derivatives as covalent inhibitors with good potency and oral activity for the treatment of solid tumors.
    Imaizumi T; Shimada I; Satake Y; Yamaki S; Koike T; Nigawara T; Kaneko O; Amano Y; Mori K; Yamanaka Y; Nakayama A; Nishizono Y; Shimazaki M; Nagashima T; Kuramoto K
    Bioorg Med Chem; 2024 Jan; 98():117581. PubMed ID: 38176113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.